Five things for pharma marketers to know: Wednesday, December 7, 2016
1. President-elect Donald Trump told Time magazine that he “doesn't like what's happened with drug prices” and that he plans to bring down the cost of prescription medications. Time named Trump its Person of the Year on Wednesday. (Time)
2. Mylan plans to lay off nearly 10% of its global workforce. A Mylan spokesperson said the job cuts are part of an efficiency strategy. (BioSpace)
3. Pfizer was fined $107 million for overcharging the U.K.'s health system for a generic epilepsy drug, phenytoin sodium. The country's antitrust regulator said that Pfizer deliberately unbranded the drug to skirt a competition law. Pfizer said it plans to appeal the ruling. (WSJ)
4. Celgene said its understanding of how its multiple myeloma drug Revlimid works in cancer patients is a boon for its R&D efforts in other diseases. The drugmaker currently has three drugs in its pipeline: CC-122 for diffuse large B-cell lymphoma, CC-220 for lupus, and CC-90009 for acute myeloid leukemia. (Bloomberg)
5. ICYMI: GlaxoSmithKline said the CEO of ViiV healthcare, Dr. Dominique Limet, will step down and that Deborah Waterhouse, the company's SVP of primary care at GSK U.S. pharmaceuticals, will succeed him. ViiV Healthcare is an HIV specialty company formed in 2009 by GSK and Pfizer.